“Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study” (2023) Swiss Medical Weekly, 153(6), p. 40090. doi:10.57187/smw.2023.40090.